What's really insane is that NIH just expanded the Lenzilumab trial Activ 5. How could NIH expand the HGEN trial and FDA not authorize Emergency Use, at the same point in time? One of the agencies is wrong and is going to have a problem over this.
Regardless, we may be supplying some of the product with the expansion.
Market Data 
Markets 
AI
